-
Mashup Score: 3Poll: Mavacamten Use in Hypertrophic Cardiomyopathy - American College of Cardiology - 19 hour(s) ago
A 63-year-old woman presents to the office for a second opinion on chronic chest pain and heart failure management. She has a medical history of mixed connective tissue disease, obstructive sleep apnea, hepatic steatosis, and long-standing hypertension diagnosed in her twenties. She reports several years of resting and exertional chest pain occurring up to five times weekly, shortness of breath with most daily activities, generalized weakness, and exercise intolerance. She has had minimal relief from
Source: www.acc.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 34
Gurusher S. Panjrath, MBBS, FACC Barbara Wiggins, PharmD, FACC Megan Coylewright, MD, MPH, FACC, Ex Officio 2. Assumptions and Proposed Definitions 4 2.1. General Clinical Assumptions 4 Figure 1. The Evaluation and Management of Clinically Suspected Myocarditis Described as a 5-Step Care Pathway 6 4. Description, Rationale, and Implication of Pathway 7 4.1. Diagnosis of Myocarditis 7 Figure 2. Three Classic Presentations of Myocarditis 8 4.2.2. Echo and Strain Echocardiography 7 4.2.3. Circulating
Source: www.jacc.orgCategories: General Medicine News, CardiologistsTweet-
Myocarditis - more unknown than known. Don't forget to check for a genetic variant, especially DSP, in recurrent disease. When to use immunosuppression? https://t.co/ebZQp5Pv2r https://t.co/Sm948QKzHw
-
-
Mashup Score: 27Myocardial inflammatory cells in cardiac amyloidosis - 14 day(s) ago
Scientific Reports – Myocardial inflammatory cells in cardiac amyloidosis
Source: www.nature.comCategories: General Medicine News, CardiologistsTweet-
An informative clinico-pathological analysis of inflammatory cells in patients with cardiac #amyloidosis Whether these findings can help explain why some patients are better at "cleaning" up fibrils vs others is yet to be seen. https://t.co/UdUPqA5dtx #CardioTwitter https://t.co/VXDKcyuJoE
-
-
Mashup Score: 11Neutrophils enhance the clearance of systemic amyloid deposits in a murine amyloidoma model - 14 day(s) ago
Amyloid-specific antibodies have been shown to opsonize and enhance amyloid clearance in systemic amyloidosis mouse models. However, the immunological mechanisms by which amyloid is removed have not been clearly defined. Previous reports from …
Source: pmc.ncbi.nlm.nih.govCategories: General Medicine News, CardiologistsTweet-
An interesting read on the mechanisms of amyloid clearance of kappa vs lambda light chains in a murine model of #amyloidosis https://t.co/wfRjqDuSaA #CardioTwitter https://t.co/zFMSJicoDH
-
-
Mashup Score: 6Recent Advances Have Improved Prognosis in ATTR-CM Patients, with Ahmad Masri, MD, MS - 21 day(s) ago
Ahmad Masri, MD, MS, discusses a study from AHA 2024 detailing changing risk profiles and outcomes in trials among patients with ATTR-CM.
Source: www.hcplive.comCategories: General Medicine News, CardiologistsTweet-
RT @HCPLiveNews: At #AHA24, @MasriAhmadMD presented new data on changing patient profile of ATTR-CM trials. https://t.co/usRvnMRGa4 #Car…
-
-
Mashup Score: 6Recent Advances Have Improved Prognosis in ATTR-CM Patients, with Ahmad Masri, MD, MS - 22 day(s) ago
Ahmad Masri, MD, MS, discusses a study from AHA 2024 detailing changing risk profiles and outcomes in trials among patients with ATTR-CM.
Source: www.hcplive.comCategories: General Medicine News, CardiologistsTweet-
RT @HCPLiveNews: At #AHA24, @MasriAhmadMD presented new data on changing patient profile of ATTR-CM trials. https://t.co/usRvnMRGa4 #Car…
-
-
Mashup Score: 19
Danon disease is a rare, X-linked, monogenic cardiomyopathy caused by mutations in the lysosomal-associated membrane 2 gene (LAMP2), which encodes the LAMP2 protein. In male patients, the predomina…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet-
Update on Danon's RP-A501 gene therapy phase I Things are going well Paper is here https://t.co/0W4Qc5eKWp #CardioTwitter https://t.co/0k7lUoIbhK
-
-
Mashup Score: 19
Danon disease is a rare, X-linked, monogenic cardiomyopathy caused by mutations in the lysosomal-associated membrane 2 gene (LAMP2), which encodes the LAMP2 protein. In male patients, the predomina…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet-
Update on Danon's RP-A501 gene therapy phase I Things are going well Paper is here https://t.co/0W4Qc5eKWp #CardioTwitter https://t.co/0k7lUoIbhK
-
-
Mashup Score: 19
Danon disease is a rare, X-linked, monogenic cardiomyopathy caused by mutations in the lysosomal-associated membrane 2 gene (LAMP2), which encodes the LAMP2 protein. In male patients, the predomina…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet-
Update on Danon's RP-A501 gene therapy phase I Things are going well Paper is here https://t.co/0W4Qc5eKWp #CardioTwitter https://t.co/0k7lUoIbhK
-
-
Mashup Score: 19
Danon disease is a rare, X-linked, monogenic cardiomyopathy caused by mutations in the lysosomal-associated membrane 2 gene (LAMP2), which encodes the LAMP2 protein. In male patients, the predomina…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet-
Update on Danon's RP-A501 gene therapy phase I Things are going well Paper is here https://t.co/0W4Qc5eKWp #CardioTwitter https://t.co/0k7lUoIbhK
-
#Mavacamten Use in #Hypertrophic #Cardiomyopathy Take this poll https://t.co/pzsx81krzZ #CardioTwitter